share_log

HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target

HC Wainwright & Co.恢复对Bellerophon Therapeutics的买入,维持30美元的目标股价
Benzinga ·  2023/05/17 06:16

HC Wainwright & Co. analyst Andrew Fein reinstates Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy and maintains $30 price target.

HC Wainwright & Co. 分析师安德鲁·费恩恢复了Bellerophon Therapeutics(纳斯达克股票代码:BLPH)的买入并维持了30美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发